Which best describes how PD-1/PD-L1 checkpoint inhibitors help treat cancer?
Choose an answer, then check it.
Clinical Pharmacology · Oncology Medications
Cancer Immunotherapies
On this page 6 sections
In 30 seconds
Cancer immunotherapies do not poison tumor cells directly; they release or redirect the patient's own immune system to attack the cancer. Checkpoint inhibitors remove brakes that let exhausted T cells resume fighting, and CAR T-cell therapy engineers T cells to hunt a specific tumor marker. Because the immune system, not the drug, causes the damage, side effects resemble autoimmune disease rather than classic chemo toxicity, and responses can unfold more slowly and unpredictably than with chemotherapy. Nursing care centers on catching new organ inflammation early and knowing it can appear long after the last dose.
The college version
Immune Checkpoint Inhibitors: Releasing the Brakes
T cells carry built-in off switches, or checkpoints, so the immune system does not attack normal tissue after clearing a threat. CTLA-4 acts early, as T cells are primed in lymph nodes; PD-1 acts later, once T cells reach tissue and meet its partner protein PD-L1. Many tumors hijack these switches so tumor-specific T cells shut down before killing cancer cells. Checkpoint inhibitors block that shutdown signal: ipilimumab blocks CTLA-4; pembrolizumab and nivolumab block PD-1; atezolizumab and durvalumab block PD-L1. With the brake released, T cells already capable of recognizing the tumor can resume attacking it.
Clinicians weigh biomarkers to estimate likelihood of response: PD-L1 expression, microsatellite instability from a defective DNA repair system that produces many abnormal proteins, and overall tumor mutational burden, since heavily mutated tumors display more antigens for T cells to notice. These are probability signals, not strict cutoffs.
Immune-Related Adverse Events
Releasing the brakes system-wide means the unleashed response is not confined to the tumor. It can inflame virtually any organ: colitis, hepatitis, pneumonitis, dermatitis, thyroiditis and other endocrinopathies, nephritis, myocarditis, and neurologic events. Hypophysitis, pituitary inflammation, deserves special note because it can permanently disrupt hormone production, requiring lifelong hormone replacement even after the drug stops. Onset can be delayed, sometimes appearing months after the last infusion, so a late symptom must still be linked back to prior therapy. Management scales with severity: mild reactions allow continued monitoring, moderate reactions mean holding the drug and starting corticosteroids, and severe reactions require stronger immunosuppression and permanent discontinuation. Because any organ can be involved, patients should carry a wallet card naming their immunotherapy and tell every clinician they are on it.
CAR T-Cell Therapy
CAR T-cell therapy engineers a patient's own collected T cells outside the body to express a receptor recognizing a specific tumor antigen, expands them, and reinfuses them after conditioning chemotherapy. Two signature toxicities follow. Cytokine release syndrome results from massive, rapid immune activation as engineered cells engage the tumor, causing fever, hypotension, and hypoxia; it is managed with tocilizumab, which blocks the interleukin-6 receptor driving the surge. Neurotoxicity is a separate signature complication needing its own monitoring. Because both can escalate quickly, this therapy is restricted to certified centers equipped for rapid critical-care response.
Other Immune-Based Approaches
Bispecific T-cell engagers bind a T cell with one arm and a tumor antigen with the other, bridging them without genetically modifying the cell. Cancer vaccines train the immune system to recognize tumor antigens, and oncolytic viruses infect and rupture tumor cells while provoking a broader antitumor response. Historically, cytokines such as interleukin-2 and interferon broadly stimulated immunity, helping some patients but causing substantial toxicity; targeted agents have largely replaced them.
Response Patterns Differ From Chemotherapy
Because immunotherapy builds a response rather than delivering an immediate cytotoxic hit, benefit can take longer to appear on scans. Imaging can also show apparent tumor growth shortly after starting therapy, called pseudoprogression, reflecting immune cells infiltrating the tumor rather than true progression. Distinguishing the two often requires continued monitoring rather than an immediate switch in therapy.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Picture your immune system as guards patrolling your body for troublemakers. To stop guards from attacking healthy cells, your body gives them a rule: if something flashes the right ID badge, stand down. Cancer cells learn to fake that badge, so guards leave them alone. Checkpoint inhibitor drugs rip away the fake badge so guards recognize the cancer as a threat again. The catch: once guards are riled up, they sometimes attack innocent parts of the body too, so doctors watch for new symptoms anywhere.
CAR T-cell therapy takes some of your own guards out of the field, shows them a wanted poster of the cancer, and sends them back as a specialized strike team. They are excellent at their one job, but when they all activate at once it can trigger a body-wide fever reaction, so doctors keep a specific medicine ready to calm it down. Because these treatments rev up your own defenses instead of a quick knockout punch like chemotherapy, shrinking the tumor can take longer, and a scan can even look worse for a while before it looks better, simply because guards are swarming in.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient completed pembrolizumab therapy four months ago and now reports new fatigue and unusual thirst. Why should this still be evaluated as a possible immune-related adverse event rather than dismissed because the drug was stopped?
Show answer
The immune brakes stay off for a while
Because these drugs unleash an ongoing immune response rather than an instant chemical effect, inflammation can surface months after the last dose, so new fatigue and thirst could reflect a delayed endocrine problem, such as thyroid or pituitary inflammation, tied to earlier treatment.
A patient starting nivolumab has a follow-up scan showing the tumor appears larger than before, yet the patient reports feeling better. What phenomenon might explain this, and why does it change how the response should be assessed?
Show answer
Pseudoprogression
The scan may show immune cells swarming into the tumor rather than the tumor truly growing, so instead of assuming treatment failure and switching therapy right away, clinicians often continue monitoring before concluding the cancer is actually progressing.
Quick check
3 questions here. Answers stay hidden until you check.
A patient on a checkpoint inhibitor develops new, persistent diarrhea. What is the correct general management principle for a suspected immune-related adverse event?
Choose an answer, then check it.
Which toxicity is most specifically associated with CAR T-cell therapy and managed with tocilizumab?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.